氧化丁宁相关的认知障碍:过度活性膀治疗的证据和影响
Michael B Chancellor1, Alvaro Lucioni2, David Staskin3
1Corewell Health Beaumont University Hospital, Oakland University William Beaumont School of Medicine, Royal Oak, MI.
Urology
|January 31, 2024
概括
氧化丁宁是一种常见的过活性膀 (OAB) 药物,由于它与大脑受体结合,可能会对记忆产生负面影响,并增加痴呆风险. 现在的指导方针建议减少其用于OAB治疗的使用.
科学领域:
- 药理学 药理学是指药理学的学科.
- 老年学是一门学科.
- 神经学 神经学
背景情况:
- 抗胆固醇药物,特别是氧丁宁,被广泛用于过度活性膀 (OAB).
- 第一代抗胆固醇药Oxybutynin与认知障碍和潜在的痴呆风险有关.
- 人们越来越担心Oxybutynin在OAB患者的长期认知影响.
研究的目的:
- 审查当前关于 oxybutynin 和认知功能之间的关系的文献.
- 检查从临床前,临床和现实研究中获得的证据.
- 讨论关于OAB治疗策略的最新建议.
主要方法:
- 关于氧丁宁和认知的临床前,临床和现实研究的文献综述.
- 对氧丁宁对肌肉蛋白受体的作用机制的分析.
- 检查流行病学数据和临床试验结果.
主要成果:
- 氧化丁氨酸与大脑中的肌肉素受体无特异地结合.
- 有证据表明,氧丁宁使用与不良认知结果之间存在联系.
- 研究表明,随着oxybutynin的暴露,痴呆的风险可能会增加.
结论:
- 氧化丁宁的抗胆性质与负面的认知影响有关.
- 建议减少对OAB的氧丁宁和类似抗胆固醇药物的使用.
- 需要进一步研究更安全的OAB治疗替代方案.
相关概念视频
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
126
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
126
Alzheimer's Disease: Treatment
193
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
193
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
675
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
675
Parkinson's Disease: Treatment
268
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
268
Alzheimer's Disease: Overview
487
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
487
Cholinergic Antagonists: Therapeutic Uses
749
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
749


